Patents by Inventor Akiko Harauma

Akiko Harauma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160067204
    Abstract: The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 10, 2016
    Inventors: Akiko HARAUMA, Fuminori KAWABATA, Toru MORIGUCHI, Tetsuya KAWAKITA, Kazuo TSUBOTA
  • Publication number: 20130245119
    Abstract: The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 19, 2013
    Applicants: KEIO UNIVERSITY, NIPPON SUISAN KAISHA, LTD.
    Inventors: Akiko Harauma, Fuminori Kawabata, Toru Moriguchi, Tetsuya Kawakita, Kazuo Tsubota
  • Publication number: 20070122452
    Abstract: Provided is a composition permitting high systemic absorption of n-3 polyunsaturated fatty acids and high transfer of them to tissues and capable of fully exhibiting pharmacological effects which the fatty acids have. A fat composition containing one or more phospholipids having, as a constituent fatty acid, an n-3 polyunsaturated fatty acid selected from docosahexaenoic acid, docosapentaenoic acid and eicosapentaenoic acid; and ?-linolenic acid and/or a fat containing ?-linolenic acid.
    Type: Application
    Filed: December 21, 2004
    Publication date: May 31, 2007
    Applicant: WAKUNAGA PHARMACEUTICLA CO., LTD
    Inventors: Toru Moriguchi, Tetsuyuki Sasaki, Akiko Harauma